cohort_watch
TL2 Member · Stuttgart, DE
UK-based. Mostly the access and pricing categories.
Joined 16 September 2025 · last posted 23h · groups: regional-uk
86 posts, newest first. Showing up to 150.
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #130 · Analytics › Home & field testing · 27 Jul 2026 · 10 likes Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #115 · Evidence › Preprints · 24 Jul 2026 · 0 likes Always label it as a preprint in any discussion. A preprint is not a published trial and it is not settled knowledge. Use it for hypothesis generation and for…
-
What a certificate commits its issuer to Replied, post #66 · Analytics › COA interpretation · 20 Jul 2026 · 2 likes Sterility testing is separate: chromatographic purity, mass spectrometry, and endotoxin testing all say nothing about whether a solution is sterile. If sterility…
-
What a reversed-phase purity number actually is Replied, post #58 · Analytics › HPLC & UHPLC · 15 Jul 2026 · 14 likes Before anything else: what was the gradient, and at what wavelength? Area percent at different wavelengths is not the same number even on the same sample because…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #92 · Sourcing › Independent verification · 15 Jul 2026 · 33 likes post #91 answers the question as asked. The question underneath it is different. Repeat testing: if you want to verify the same lot a second time, testing with a…
-
Pooling trials with different estimands Replied, post #80 · Evidence › Meta-analyses · 8 Jul 2026 · 8 likes Picking up post #77: that is the part I would want checked first. Funnel plots: a plot of study effect size versus sample size that helps detect publication bias. If…
-
How shortages have affected compounding permissions — does this still hold? Replied, post #20 · Access › Shortages · 1 Jul 2026 · 10 likes This follows post #17 rather than contradicting it. Compounding during shortages: some jurisdictions allow pharmacy compounding when a marketed product is in shortage.…
-
Insomnia at a dose step: reported experiences — the long version Replied, post #40 · Wellbeing › Sleep · 29 Jun 2026 · 25 likes I read post #38 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
[2026 update] Waist circumference technique and its repeatability Replied, post #20 · Outcomes › Progress reports · 27 Jun 2026 · 11 likes Protein intake and resistance training: both self-reported and therefore optimistic in most reports. Recording them anyway creates a record you can look back on.
-
Second pass at: Metformin co-administration and additive GI effects Replied, post #132 · Practice › Interactions · 23 Jun 2026 · 0 likes SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
-
Publication patterns in the BPC-157 literature, examined Replied, post #15 · Compounds › Repair & healing peptides · 17 Jun 2026 · 1 like Coming back to post #13, because the follow-up matters more than the original answer. What would change the position on repair peptides: adequately powered, published,…
-
Comparing prices across jurisdictions without misleading yourself Replied, post #42 · Access › Pricing · 5 Jun 2026 · 25 likes Compute cost per delivered dose at your dose if you want a number you can act on. That requires knowing your dose, vial volume, and whether you are using a vial or a pen.
-
Micronutrient adequacy at low total intake Replied, post #3 · Nutrition & Training › Protein & intake · 5 Jun 2026 · 0 likes On the opening post — agreed on the reasoning, with one qualification. Meeting protein targets on suppressed appetite: this is where the practical difficulty lies.…
-
Reference intervals: how they are constructed and why one in twenty flags — does this… Replied, post #2 · Clinical › Bloodwork · 3 Jun 2026 · 11 likes Coming back to the opening post, because the follow-up matters more than the original answer. HbA1c and glucose: HbA1c reflects average glucose over months; a spot…
-
A plateau that disappeared when I changed how I measured — the long version Replied, post #44 · Outcomes › Progress reports · 30 May 2026 · 9 likes Plateaus and resets: if weight loss stalls and then resumes, that is ordinary. It is not evidence that the medication stopped working. It is not evidence that it is…
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #60 · Evidence › Journal club · 18 May 2026 · 12 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Residual solvents and scavengers: what is looked for — what changed since Replied, post #39 · Analytics › Impurities & related substances · 13 May 2026 · 11 likes post #38 answers the question as asked. The question underneath it is different. Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier.…
-
How this community labels and discusses unrefereed work — the long version Replied, post #11 · Evidence › Preprints · 12 May 2026 · 19 likes Peer review as a filter: published papers have survived a review process that rejects many submissions. Preprints have not. Neither guarantees correctness, but…
-
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #33 · Devices › Syringes & needles · 6 May 2026 · 0 likes Needle gauge: smaller numbers (30G) are finer and less painful. Larger numbers (25G) are courser. For subcutaneous injection, 27-30G is typical. Finer needles take…
-
Manufacturer assistance programmes and their eligibility rules Replied, post #21 · Access › Pricing · 27 Apr 2026 · 6 likes Cost per milligram is the only comparison that survives format differences, but even then it needs care. A pen and a vial are not the same product and cannot be…
-
Managing an unplanned gap in supply Replied, post #85 · Access › Shortages · 4 Apr 2026 · 7 likes Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are…
-
Measurement error in home scales, with a worked standard deviation — the long version Replied, post #69 · Research Methods › Statistics · 3 Apr 2026 · 1 like post #68 answers the question as asked. The question underneath it is different. P-values and significance: p
-
Type 2 diabetes and the largest part of the evidence base Replied, post #53 · Clinical › Comorbidities · 3 Apr 2026 · 1 like Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents,…
-
Grapefruit: why this class is not the class that cares Replied, post #101 · Practice › Interactions · 31 Mar 2026 · 0 likes post #100 answers the question as asked. The question underneath it is different. Supplements and herbs: many have no established interaction. Some do. If you are…
-
Air bubbles in a subcutaneous injection: the honest risk assessment — does this still… Replied, post #18 · Practice › Administration · 15 Mar 2026 · 1 like Picking up post #15: that is the part I would want checked first. A site rotation scheme that actually works: abdomen, outer thigh, back of arm, outer hip. Rotate…
-
Reading a preclinical wound-healing model and its relevance to a human tendon — a second… Replied, post #31 · Compounds › Repair & healing peptides · 10 Mar 2026 · 14 likes post #30 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
The most common factual error about semaglutide on the internet — what changed since Replied, post #44 · Compounds › Semaglutide · 8 Mar 2026 · 0 likes Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and…
-
Air bubbles in a subcutaneous injection: the honest risk assessment — does this still… Replied, post #6 · Practice › Administration · 28 Feb 2026 · 30 likes Coming back to post #4, because the follow-up matters more than the original answer. Injecting into an area that has become firm: lipohypertrophy — thickened fatty…
-
Can a home kit substitute for a laboratory report? A careful no Replied, post #130 · Analytics › Home & field testing · 9 Feb 2026 · 0 likes Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based assay can work. These are sometimes available commercially but are…
-
Molecular mass of semaglutide and why the figure differs between sources Replied, post #3 · Compounds › Semaglutide · 8 Feb 2026 · 14 likes The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the…
-
[2026 update] Evidence quality in the secretagogue literature: an honest assessment Replied, post #19 · Compounds › Secretagogues & GH axis · 3 Feb 2026 · 4 likes Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is…
-
Distinguishing expected GI effects from something that needs urgent attention Replied, post #96 · Practice › Side effects · 14 Jan 2026 · 11 likes Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during…
-
Measurement error in home scales, with a worked standard deviation — the long version Replied, post #7 · Research Methods › Statistics · 4 Jan 2026 · 25 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Adsorption to container surfaces and to plastics Replied, post #3 · Pharmacology › Formulation chemistry · 4 Jan 2026 · 0 likes post #2 is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Non-inferiority margins: how they are chosen and how they are abused Replied, post #30 · Evidence › Trials · 31 Dec 2025 · 19 likes Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between…
-
Follow-up: Bug report: the reconstitution calculator and a rounding edge case Replied, post #8 · Data & Tools › Calculators · 23 Dec 2025 · 3 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like Replied, post #18 · Compounds › Semaglutide · 23 Dec 2025 · 0 likes Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but…
-
Coming back to: Private prescribing in the UK: what is actually involved Replied, post #7 · Regional › UK & Ireland · 23 Dec 2025 · 12 likes I read post #5 twice before replying, because I had assumed the opposite. Private prescribing is legal and widespread, including through remote consultation. Pharmacies…
-
[2026 update] Whether protein timing matters at a large deficit Replied, post #8 · Nutrition & Training › Protein & intake · 19 Dec 2025 · 0 likes post #7 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Dose numbers for oral formulations are not comparable to injectable ones Replied, post #4 · Compounds › Oral incretins · 17 Nov 2025 · 8 likes Worth separating two things that post #3 runs together. SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local…
-
Reading SURMOUNT-1 without the press release Replied, post #36 · Compounds › Tirzepatide · 17 Oct 2025 · 11 likes Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly…
-
Compounds this community declines to help with, and why Replied, post #60 · Compounds › Other compounds · 4 Oct 2025 · 21 likes Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation…
-
AOD-9604 and the fragment hypothesis, revisited Replied, post #17 · Compounds › Other compounds · 27 Sep 2025 · 5 likes On post #13 — agreed on the reasoning, with one qualification. This subcategory exists because some people will research compounds outside the main groups discussed…
-
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #94 · Evidence › Study critique · 15 Sep 2025 · 9 likes Coming back to post #92, because the follow-up matters more than the original answer. Bias towards the null and bias away from the null: different criticisms have…
-
[2026 update] What we do not know about retatrutide, listed explicitly Replied, post #84 · Compounds › Retatrutide · 8 Sep 2025 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
Aggregated purity results across four services, with caveats — a second dataset Started this topic · Data & Tools › Datasets · 5 Sep 2025 · 6 likes Aggregated purity results across four services, with caveats — a second dataset — setting out what I have, and where I think it stops being reliable. Working through…
-
Power cut for eleven hours: how I assessed it afterwards Replied, post #28 · Practice › Storage & stability · 19 Aug 2025 · 1 like Beyond-use dating: the date after which a prepared solution should not be used. It is an estimate based on how fast the solution degrades under stated storage, not on…
-
When a preprint is the best available evidence and we say so Replied, post #48 · Evidence › Preprints · 12 Aug 2025 · 3 likes How to cite a preprint: author last name, first initial, et al. Title. Server name [preprint]. Posted date. Doi. Include the server name and note that it is a preprint.
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #90 · Compounds › Retatrutide · 5 Aug 2025 · 8 likes Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not…
-
How to research a compound with no human data without deceiving yourself Replied, post #116 · Compounds › Other compounds · 5 Aug 2025 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Antibiotics and a course of something with delayed emptying Replied, post #103 · Practice › Interactions · 29 Jul 2025 · 5 likes post #102 answers the question as asked. The question underneath it is different. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Revisiting: German, French and Dutch differences, compared Replied, post #49 · Regional › European Union · 24 Jul 2025 · 16 likes Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme…
-
A field-by-field walk through a certificate of analysis Replied, post #55 · Analytics › COA interpretation · 16 Jul 2025 · 0 likes When a document puts the specification in the result column, it has told you the release criterion, not the measurement. Those are different claims and the second is…
-
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #54 · Compounds › Semaglutide · 4 Jul 2025 · 15 likes The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no…
-
Hepatic steatosis: what the MASH trial evidence supports Replied, post #68 · Clinical › Comorbidities · 18 Jun 2025 · 8 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
BPC-157: what the rodent literature actually shows, and what it does not — a second… Replied, post #53 · Compounds › Repair & healing peptides · 3 Jun 2025 · 0 likes Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does…
-
Substitution between formats during a shortage Replied, post #5 · Access › Shortages · 2 Jun 2025 · 9 likes Picking up post #2: that is the part I would want checked first. International supply chains: a shortage in one country does not mean shortage in another. That is why…
-
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #6 · marked as the solution · Compounds › Oral incretins · 1 Jun 2025 · 6 likes Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is…
-
DXA precision and the least significant change for lean mass — the long version Replied, post #108 · Outcomes › Body composition · 28 May 2025 · 22 likes Maintenance phase: tracking body composition during maintenance (weight stable) is different from tracking during active loss. Changes are smaller and precision becomes…
-
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #36 · Sourcing › Independent verification · 10 May 2025 · 1 like Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not…
-
[2026 update] Citation sweep results: how many references did not say what was claimed Replied, post #27 · Meta › Wiki maintenance · 5 May 2025 · 33 likes I read post #25 twice before replying, because I had assumed the opposite. Evidence synthesis: if you think a page should cover recent evidence or a new development,…
-
Reporting a disappointing outcome, and why it belongs here Replied, post #12 · Outcomes › Progress reports · 3 May 2025 · 3 likes Worth separating two things that post #8 runs together. Non-scale victories: muscle gain or maintenance, clothing fit, energy level, and capability (like climbing…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #6 · Evidence › Journal club · 16 Apr 2025 · 1 like Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
When to suspect the method rather than the sample Replied, post #108 · Analytics › Method validation · 3 Apr 2025 · 20 likes System suitability: injections run at the start of a batch to establish that the instrument and column are performing. Acceptance criteria typically include replicate…
-
Obstructive sleep apnoea and a hard endpoint in this class Replied, post #43 · Clinical › Comorbidities · 27 Mar 2025 · 20 likes Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct…
-
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? Replied, post #61 · Evidence › Journal club · 23 Mar 2025 · 0 likes SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes. The first outcome trial in people without diabetes, which decoupled the cardiovascular…
-
Review: a draft on reconstitution arithmetic, with objections Replied, post #69 · Documentation › Doc review · 22 Mar 2025 · 26 likes New maintainer recruitment: if a page's maintainer is inactive and updates are needed, suggesting a new maintainer here can help transition responsibility.
-
Individual participant data versus aggregate data Replied, post #23 · Evidence › Meta-analyses · 20 Mar 2025 · 11 likes post #22 is right about the mechanism and I think understates the practical bit. When a meta-analysis is unhelpful: if the included studies are heterogeneous in…
-
A promotion I argued against, and why I lost Replied, post #128 · Documentation › Doc review · 11 Mar 2025 · 4 likes post #127 answers the question as asked. The question underneath it is different. Interdependencies: if updating one page requires updating related pages, posting that…
-
Charge states for a 4 kDa peptide, worked through Replied, post #12 · Analytics › Mass spectrometry · 3 Mar 2025 · 27 likes Charge states observed: for semaglutide (4113.6 Da) the doubly charged ion appears at m/z ≈ 2057, triply charged at ≈ 1371, quadruply at ≈ 1029. Those are the positions…
-
Adducts: sodium, potassium, and the peak you did not expect Replied, post #23 · Analytics › Mass spectrometry · 2 Mar 2025 · 0 likes Resolution: "high resolution" commonly means
-
Introducing myself and asking whether my planned first topic belongs anywhere Replied, post #11 · Start Here › Welcome · 28 Feb 2025 · 28 likes Trust levels accumulate over time and they give you access to small things like the ability to edit your own posts without a timestamp. They are not a status symbol and…
-
Follow-up: What other technical communities get right that we do not Replied, post #10 · Lounge › Off topic · 3 Feb 2025 · 9 likes Not a rules-free zone: the guidelines still apply. No phones, no Telegram, no endorsements of other communities. Just a relaxed bar for how directly the topic needs to…
-
Recovery when intake is low: what to cut first Replied, post #49 · Nutrition & Training › Resistance training · 12 Jan 2025 · 22 likes I read post #47 twice before replying, because I had assumed the opposite. Cardio and resistance: the interaction between energy-intense cardiovascular training and…
-
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #121 · Compounds › Tirzepatide · 31 Dec 2024 · 0 likes Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a…
-
People with a low starting BMI: where the evidence stops Replied, post #28 · Clinical › Special populations · 29 Dec 2024 · 20 likes Hepatic impairment: less is known about dosing in significant liver disease than in kidney disease. Extreme caution applies because the liver metabolises a large…
-
[2026 update] New subcategory: rationale and scope Replied, post #88 · Meta › Announcements · 23 Dec 2024 · 32 likes This follows post #85 rather than contradicting it. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The…
-
When "no data" is the complete and final answer Replied, post #48 · Compounds › Other compounds · 23 Dec 2024 · 14 likes On post #44 — agreed on the reasoning, with one qualification. Compounds this community declines to help with, and why: there are specifics in the guidelines and they…
-
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #130 · Compounds › Repair & healing peptides · 23 Nov 2024 · 1 like TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation…
-
Coming back to: The nausea timeline across the first four weeks, with a tabulated log Replied, post #25 · Practice › Side effects · 6 Nov 2024 · 28 likes Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping…
-
Time to steady state after a dose increase Replied, post #115 · Pharmacology › Pharmacokinetics · 5 Nov 2024 · 0 likes Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady…
-
Requesting a page: what makes a good request — what changed since Replied, post #59 · Documentation › Wiki requests · 11 Oct 2024 · 21 likes Coming back to post #57, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
-
Progressive overload when the scale is falling — one year on Replied, post #103 · Nutrition & Training › Resistance training · 29 Sep 2024 · 0 likes Picking up post #100: that is the part I would want checked first. Adaptation and plateau: if strength does not change for weeks, that is stability, not backsliding.…
-
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #31 · Clinical › Bloodwork · 15 Sep 2024 · 22 likes post #30 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than…
-
Correlation in a self-tracked dataset: what it can support Replied, post #94 · Research Methods › Statistics · 24 Aug 2024 · 0 likes Regression to the mean: if you select people with extreme values (very high or very low), their next measurement is often less extreme just by chance. This can look…
-
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #10 · Practice › Dosing & titration · 6 Jul 2024 · 17 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…